Legal status · United States
Is BGE-102 legal in the United States?
No. BGE-102 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
BGE-102 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Investigational; Phase 1/2 |
| Evidence level | Preliminary (research strength: Preliminary) |
| Reviewed | Sep 2026 |
Classification and note come from the BGE-102 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
BGE-102 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BGE-102 is
BioAge's brain-penetrant NLRP3 inhibitor that cut the inflammation marker hsCRP by a median 86% in two weeks in Phase 1, the strongest human anti-inflammaging signal from a geroscience company so far.
NLRP3 is the inflammasome that drives IL-1beta and much of the chronic low-grade inflammation of aging. In a Phase 1 reported in April 2026, 120 mg of BGE-102 daily lowered hsCRP by a median 86% by day 14 in adults with obesity and elevated inflammation, with only mild to moderate adverse events.
Mechanism: Small-molecule inhibition of the NLRP3 inflammasome, blocking caspase-1 activation and IL-1beta release.
Regulatory history: Investigational; Phase 1/2
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for BGE-102 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BGE-102 in other countries
Frequently asked questions
Is BGE-102 legal in the United States?
No. BGE-102 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy BGE-102 in the United States?
No approved product exists to buy. In the United States BGE-102 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is BGE-102 FDA approved?
No. FDA status: Investigational; Phase 1/2. Current US classification: "Investigational, not approved". Evidence level: Preliminary.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BGE-102 live on its compound profile.
BGE-102 profileThis page is general information about the regulatory status of BGE-102 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.